October 2017

Ipsen data show CP spasticity undertreated

A presentation given by Basking Ridge, NJ-based Ipsen Biopharmaceuticals in September at the annual meeting of the American Academy of Cerebral Palsy and Developmental Medicine in Montreal, Canada, found more than 40% of children with cerebral palsy (CP) receive none of 10 common therapies for the motor disorder.

The retrospective study analyzed two years (2013-2015) of Medicaid data from a seven-million-person database, identifying 3294 unique cases of children with CP; 42% of these children didn’t receive any of 10 therapies identified by an expert panel as those most commonly used for spasticity management. The therapies are physical therapy, orthotic devices, oral baclofen, botulinum toxin, antispasm medication, casting, orthopedic surgery, baclofen injection, baclofen pumps, and rhizotomies.

The data also showed children with CP who were likely nonambulatory had average annual costs four times higher than those for children with CP who were likely ambulatory (ambulation status could not be obtained so researchers used an algorithm to estimate its likelihood).

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.